Psychedelics Investing Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition
Psychedelics Investing Optimi Health to Supply MDMA to MAPS Israel's Clinical Trial for Trauma-Related PTSD
Psychedelics Investing Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months
Psychedelics Investing NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression
Psychedelics Investing Right Season Investments Engages MCS Market Communication Service to Provide Market Support
Psychedelics Investing Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025
life science investing Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock
Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition
